Ann: Significant Immunological Outcomes in BIT225 HIV-1 Trial, page-187

Among the different markers of HIVpersistence in infected cells, total HIV DNA is to date the most widely used. It allows an overall quantification of all viral forms of HIV DNA in infected cells, each playing a different role.

Viral reservoir size refers to cellular human immunodeficiency virus-1 (HIV-1) DNA levels in CD4+ T lymphocytes of peripheral blood obtained from patients with plasma HIV-1-RNA levels (viral load, VL) maintained below the detection limit by antiretroviral therapy (ART)

"The  trial  was  designed  to  assess  the  safety  and  antiviral  activity  of  three  month’s  dosing  of  BIT225  in combination  with  antiretroviral  drugs  in  treatment-naïve  HIV-positive  subjects"

What levels of HIV DNA reduction did this trial achieve ??

They need to measure the level of delay in HIV viral rebound after BIT255 treatment interruption. When are they doing this.

At this stage a unique effect in several patients in a small trial is all they have. This is no where near a cure yet imo.

They claim to have removed some virus from macrophage cells. What is the effect of this on these patients.  Does the virus return to these cells when you stop taking BIT255 ?

Obviously longer term studies would be needed to show immune responses of removal of virus from macrophage cells on cognitive effects.

Will they get funding from big pharma ? . If they thought they had something they could have easily raised further funds to do more trials and then sell out for much more money.